Stelara (ustekinumab; Janssen Biotech Inc.) for treatment of psoriatic arthritis

Record ID 32014000404
Authors' recomendations: Psoriasis is a chronic inflammatory disorder characterized by red, scaly skin lesions that are typically located on the elbows, knees, lower back, and umbilical area. Some patients with psoriasis develop psoriatic arthritis (PsA), which is a seronegative inflammatory spondyloarthropathy (spondylarthritis, or inflammation of the vertebral column). The incidence of PsA in patients with psoriasis is unclear but is estimated to range from 10% to 30%. Psoriasis is the most prevalent autoimmune disease in the United States and causes significant functional impairment and affects quality of life. Symptoms of PsA are edema, pain, tenderness, and stiffness of joints, ligaments, and tendons. The severity can vary from a mild oligoarticular form affecting a few joints to a severe erosive polyarticular form that is associated with deformities in numerous joints. Mild forms of PsA may be treated with nonsteroidal anti-inflammatory drugs (NSAIDs) and intra-articular glucocorticoid injections, which may relieve the symptoms but do not significantly alter disease progression. Approximately 50% of patients with PsA progress to an advanced stage of disease with joint destruction. Moderate to severe forms of PsA are treated with disease-modifying antirheumatic drugs (DMARDs), particularly methotrexate, and monoclonal antibodies to tumor necrosis factor (TNF).
Project Status: Completed
Year Published: 2013
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: United States
MeSH Terms
  • Antibodies, Monoclonal, Humanized
Organisation Name: HAYES, Inc.
Contact Address: 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
Contact Email:
Copyright: 2013 Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.